Could Trillium Fall Below $10 in 2021?
Small biotech companies have notoriously volatile stocks. Positive results from early lab work or clinical trials can fuel investors' imaginations. It doesn't hurt that every once in a while a company can seem to discover medicinal gold as it parlays a discovery into a blockbuster drug or multibillion-dollar acquisition. Trillium Therapeutics (NASDAQ: TRIL) is proving no different. The stock has seen highs and lows that would give most shareholders whiplash. Shares of Trillium sat at $0.24 last December before rocketing higher to $21 at the end of November. Since then, the stock has fallen 44% from that high. Investors want to know if it could fall below $10 per share.
Image source: Getty Images.
Trillium's journey started last year with a new CEO and a doubling down on a potential treatment for blood cancers. The focus paid off. Early results from a phase 1 study in January showed the company's two drug candidates, TTI-621 and TTI-622, demonstrated the ability to block the signal that nearly all cancer cells use to cloak themselves from the immune system. That was enough to get Pfizer's (NYSE: PFE) attention. The drug giant invested $25 million into Trillium in September. Investors have plenty of reason to be excited.
Source Fool.com
